LRRK2 inhibitors are envisaged to be administered not only to LRRK2-PD patients, but also to idiopathic PD patients, as indicated by the increase of pS1292-LRRK2 levels in urinary exosomes and brain tissue57,77. The gene discussed is LRRK2; the disease is Parkinson disease.